Repaglinide is a short-acting insulin secretagogue that lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on functional beta cells in the pancreatic islets. Repaglinide binds to receptors on beta cells to close ATP-dependent potassium channels in the beta cell membrane, depolarizes beta cells, opens calcium channels, and increases the influx of calcium, thereby inducing beta cells to secrete insulin. After oral administration of repaglinide, patients with type 2 diabetes experience an insulin secretion response within 30 minutes after a meal, causing blood sugar to drop during meals. Plasma repaglinide levels drop rapidly, and 4 hours after taking the drug, the drug concentration in the plasma of patients with type 2 diabetes is very low. Studies have shown that when patients with type 2 diabetes take 0.5-4 mg of repaglinide, blood sugar concentrations decrease in a dose-dependent manner.

This product is a paramagnetic contrast agent used for magnetic resonance imaging. After entering the body, it can shorten the T1 and T2 relaxation times of protons in tissues, thereby enhancing image clarity and contrast.

This product is a paramagnetic contrast agent used for magnetic resonance imaging. After entering the body, it can shorten the T1 and T2 relaxation times of protons in tissues, thereby enhancing image clarity and contrast.